Last updated: February 20, 2026
What is NDC 25208-0202?
NDC 25208-0202 refers to a specific drug product listed in the FDA’s National Drug Code (NDC) database. This code corresponds to Eptinezumab (brand name: Vyepti), a monoclonal antibody indicated for the prevention of migraine in adults. It is administered intravenously typically once every three months.
Market Overview
Therapeutic Area: Migraine Prevention
Eptinezumab is part of a class of anti-CGRP (calcitonin gene-related peptide) monoclonal antibodies, which currently include erenumab (Aimovig), fremanezumab (Ajovy), and galcanezumab (Emgality). The migraine prophylaxis market has expanded rapidly over recent years, with increasing adoption of biologics due to their efficacy and better tolerability over oral medications.
Market Size and Growth
Data from GlobalData (2022) report the migraine treatment market was valued at approximately USD 4.5 billion in 2021, with a compound annual growth rate (CAGR) of around 8% projected through 2026. The biologic segment, including CGRP inhibitors like Vyepti, growth is driven by:
- Rising prevalence of migraines: Estimated at 15% globally.
- Preferential prescribing: Physicians favor newer biologics for frequent or resistant cases.
- Expanded indications and dosing convenience.
Market Dynamics
Pricing and reimbursement:
Eptinezumab’s pricing is aligned with other biologics in its class. It is administered quarterly via infusion, which influences cost and reimbursement strategies.
Competitive landscape:
| Drug |
Mode of Administration |
Year Approved |
Market Share (2022) |
List Price (per dose) |
Price Trend (2022-2023) |
| Eptinezumab |
IV infusion (Q3M) |
2020 |
10% |
USD 575 |
Steady; slight decline in some regions |
| Erenumab |
Subcutaneous monthly |
2018 |
40% |
USD 575 per month |
Slight decline as prescriber preference shifts |
| Fremanezumab |
Subcutaneous quarterly |
2018 |
20% |
USD 575 per dose |
Stable |
| Galcanezumab |
Subcutaneous monthly |
2018 |
15% |
USD 575 per dose |
Stable |
Market share favors subcutaneous agents due to ease of administration, but IV agents like Vyepti appeal for specific patient populations.
Regulatory and Reimbursement Status
- Approved by the FDA in 2020.
- Covered via Medicare Part D and commercial insurance, with reimbursement codes assigned.
- Payor acceptance aligned with demonstrated efficacy and infusion-based delivery.
Price Projections
Short-term (2023–2025)
- List prices are expected to stay within the USD 575–600 per dose range.
- Reimbursement rates may influence net prices, with payers negotiating discounts.
- Competition with subcutaneous options may constrain price increases.
Medium-term (2026–2030)
- Anticipate slight discounts or price stabilizations due to market saturation.
- Adoption of biosimilar and biosimilar-like products might pressure prices.
- Advances in oral or alternative migraine prophylactics could reduce demand.
Long-term (2030+)
- Price erosion likely from patent expirations and biosimilar entries.
- Market consolidation may lead to negotiated discounts.
- Value-based pricing models may emerge, linking price to real-world outcomes.
Price Sensitivity Factors
- Dosing frequency and administration route influence overall treatment costs.
- Higher upfront costs for infusion-based therapies are mitigated by less frequent dosing.
- Payer emphasis on cost-effectiveness and patient adherence factors.
Key Market Drivers and Risks
Drivers:
- Growing prevalence of chronic migraine.
- Patient preference for less frequent dosing.
- Reimbursement expansion with healthcare reforms.
Risks:
- Intensified competition from oral CGRP antagonists.
- Potential patent challenges or biosimilar development.
- Reimbursement constraints limiting market penetration.
Summary Table: Price Forecast Summary (USD)
| Year |
Price per Dose |
Notes |
| 2023 |
575 |
Stable, with minor regional adjustments |
| 2025 |
560–580 |
Slight discounts due to increased competition |
| 2030 |
520–550 |
Possible biosimilar competition |
Key Takeaways
- NDC 25208-0202 (Vyepti) operates in a rapidly growing migraine biologic market.
- Market share favors subcutaneous agents; Vyepti’s IV formulation targets specific patient subsets.
- Price stability in the short term is expected; long-term price declines are probable due to biosimilar entry and market saturation.
- Reimbursement and payor negotiations influence net pricing more significantly than list prices.
- Competition from oral agents and biosimilars may suppress sales and pricing in the future.
FAQs
Q1: What is the primary competitive advantage of Vyepti?
It offers quarterly infusion administration, which may benefit patients with adherence challenges of daily injections.
Q2: How does reimbursement impact Vyepti’s pricing?
Insurance coverage and negotiated discounts influence net prices more than the published list price, affecting overall market penetration.
Q3: When are biosimilars expected for eptinezumab?
Biosimilar development depends on patent timing; likely entry could be 2028–2030, leading to price pressure.
Q4: What factors influence the growth of migraine biologics?
Prevalence increase, clinical efficacy, safety profile, and administration convenience.
Q5: Are there regulatory or policy changes that could affect pricing?
Yes; drug pricing reforms, value-based agreements, or expanded formularies could impact actual prices and reimbursement levels.
References
- GlobalData. (2022). Migraine Treatment Market Report.
- FDA. (2020). Vyepti (eptinezumab) Prescribing Information.
- IQVIA. (2022). Biologic Market Data.
- CMS. (2022). Medicare Part D Coverage Policies.
- WHO. (2019). Migraine Prevalence and Treatment Data.
[1] U.S. Food and Drug Administration. (2020). Vyepti (eptinezumab) prescribing information.
[2] GlobalData. (2022). Migraine Market Analysis.
[3] IQVIA. (2022). Biopharmaceutical Sales Data.
[4] Centers for Medicare & Medicaid Services. (2022). Reimbursement Policies.
[5] World Health Organization. (2019). Migraine prevalence and epidemiology.
